Regulation of heparanase expression in coronary artery disease in diabetic, hyperlipidemic swine
Name
Edelman_Regulation of.pdf
Size
1.35 MB
Format
Adobe PDF
Checksum (MD5)
7e1657ccbd3411dc39953968cf93a15e
Author(s)
Baker, Aaron B.
Chatzizisis, Yiannis S.
Beigel, Roy
Jonas, Michael
Stone, Benjamin V.
Coskun, Ahmet U.
Maynard, Charles
Rogers, Campbell
Koskinas, Konstantinos C.
Feldman, Charles L.
Date Issued
September 2010
Journal
Atherosclerosis
Publisher
Elsevier
Citation
Baker, Aaron B., Yiannis S. Chatzizisis, Roy Beigel, Michael Jonas, Benjamin V. Stone, Ahmet U. Coskun, Charles Maynard, et al. “Regulation of Heparanase Expression in Coronary Artery Disease in Diabetic, Hyperlipidemic Swine.” Atherosclerosis 213, no. 2 (December 2010): 436–442.
Version
Author's final manuscript
Abstract
Objective
Enzymatic degradation of the extracellular matrix is known to be powerful regulator of atherosclerosis. However, little is known about the enzymatic regulation of heparan sulfate proteoglycans (HSPGs) during the formation and progression of atherosclerotic plaques.
Methods and results
Swine were rendered diabetic through streptozotocin injection and hyperlipidemic through a high fat diet. Arterial remodeling and local endothelial shear stress (ESS) were assessed using intravascular ultrasound, coronary angiography and computational fluid dynamics at weeks 23 and 30. Coronary arteries were harvested and 142 arterial subsegments were analyzed using histomorphologic staining, immunostaining and real time PCR. Heparanase staining and activity was increased in arterial segments with low ESS, in lesions with thin cap fibroatheroma (TCFA) morphology and in lesions with severely degraded internal elastic laminae. In addition, heparanase staining co-localized with staining for CD45 and MMP-2 within atherosclerotic plaques. Dual staining with gelatinase zymography and heparanase immunohistochemical staining demonstrated co-localization of matrix metalloprotease activity with heparanase staining. A heparanase enzymatic activity assay demonstrated increased activity in TCFA lesions, subsegments with low ESS and in macrophages treated with oxidized LDL or angiotensin II.
Conclusions
Taken together, our results support a critical role for heparanase in the development of vulnerable plaques and suggest a novel therapeutic target for the treatment of atherosclerosis.
MIT Department
Harvard University--MIT Division of Health Sciences and Technology
Terms of Use
Creative Commons Attribution-Noncommercial-NoDerivatives
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1016/j.atherosclerosis.2010.09.003
